Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus

LP-310 Treatment Demonstrates Clinically Meaningful Reductions in Pain, Ulceration, and Inflammation Across All Key Metrics

Findings Highlight Favorable Safety Profile and Tolerability of Twice-Daily Oral Rinse

Read more at globenewswire.com